BACKGROUND: The significance of hepatitis B core antibody (anti-HBc) without hepatitis B surface antigen (HBsAg) or hepatitis B surface antibody (anti-HBs) is unclear. METHODS: This cohort study included men enrolled in the Multicenter AIDS Cohort to determine clinical and laboratory predictors of isolated anti-HBc. RESULTS: A total of 2286 subjects (51% human immunodeficiency virus [HIV]-infected) were followed over 3.9 years. Overall, 16.9% (387) had at least 1 visit with isolated anti-HBc. The isolated anti-HBc pattern was stable 84% of the time, and transitioned to or from a pattern of past infection (anti-HBc and anti-HBs). Isolated anti-HBc was associated with HIV infection (odds ratio [OR], 2.19; 95% confidence interval [CI], 1.73-2.79) and hepatitis C virus (HCV; OR, 4.21; 95% CI; 2.99-5.91). The HCV association was stronger for chronic HCV infection (OR, 6.76; 95% CI, 5.08-8.99) than for cleared HCV (OR, 3.03; 95% CI, 1.83-5.03). HIV infection, chronic HCV, and cleared HCV infection all remained associated with isolated anti-HBc in multivariable models (OR, 1.74; 95% CI, 1.33-2.29; OR, 6.24; 95% CI, 4.62-8.42; and OR, 2.77; 95% CI, 1.65-4.66, respectively). Among HIV-infected subjects, highly active antiretroviral therapy was negatively associated (OR, 0.79; 95% CI, .66-.95) with isolated anti-HBc. CONCLUSIONS: Isolated anti-HBc is associated with HIV and HCV coinfection, especially active HCV replication, and most commonly occurs as a transition to or from the pattern of natural immunity (anti-HBc and anti-HBs). The isolated anti-HBc pattern likely represents resolved HBV infection with low or undetected anti-HBs.
BACKGROUND: The significance of hepatitis B core antibody (anti-HBc) without hepatitis B surface antigen (HBsAg) or hepatitis B surface antibody (anti-HBs) is unclear. METHODS: This cohort study included men enrolled in the Multicenter AIDS Cohort to determine clinical and laboratory predictors of isolated anti-HBc. RESULTS: A total of 2286 subjects (51% human immunodeficiency virus [HIV]-infected) were followed over 3.9 years. Overall, 16.9% (387) had at least 1 visit with isolated anti-HBc. The isolated anti-HBc pattern was stable 84% of the time, and transitioned to or from a pattern of past infection (anti-HBc and anti-HBs). Isolated anti-HBc was associated with HIV infection (odds ratio [OR], 2.19; 95% confidence interval [CI], 1.73-2.79) and hepatitis C virus (HCV; OR, 4.21; 95% CI; 2.99-5.91). The HCV association was stronger for chronic HCV infection (OR, 6.76; 95% CI, 5.08-8.99) than for cleared HCV (OR, 3.03; 95% CI, 1.83-5.03). HIV infection, chronic HCV, and cleared HCV infection all remained associated with isolated anti-HBc in multivariable models (OR, 1.74; 95% CI, 1.33-2.29; OR, 6.24; 95% CI, 4.62-8.42; and OR, 2.77; 95% CI, 1.65-4.66, respectively). Among HIV-infected subjects, highly active antiretroviral therapy was negatively associated (OR, 0.79; 95% CI, .66-.95) with isolated anti-HBc. CONCLUSIONS: Isolated anti-HBc is associated with HIV and HCV coinfection, especially active HCV replication, and most commonly occurs as a transition to or from the pattern of natural immunity (anti-HBc and anti-HBs). The isolated anti-HBc pattern likely represents resolved HBV infection with low or undetected anti-HBs.
Authors: D Neau; M Winnock; T Galpérine; A C Jouvencel; L Castéra; E Legrand; E Tranchant; E Balestre; D Lacoste; J M Ragnaud; M Dupon; M E Lafon; F Dabis Journal: HIV Med Date: 2004-05 Impact factor: 3.180
Authors: Rajesh T Gandhi; Alysse Wurcel; Hang Lee; Barbara McGovern; Melinda Boczanowski; Roslyn Gerwin; Colleen P Corcoran; Zbigniew Szczepiorkowski; Sarah Toner; Daniel E Cohen; Paul E Sax; Chinweike Ukomadu Journal: Clin Infect Dis Date: 2003-06-06 Impact factor: 9.079
Authors: Audrey L French; Anna Hotton; Mary Young; Marek Nowicki; Michael Augenbraun; Kathryn Anastos; Eric Seaberg; William Rosenberg; Marion G Peters Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Amy E Greer; San-San Ou; Ethan Wilson; Estelle Piwowar-Manning; Michael S Forman; Marybeth McCauley; Theresa Gamble; Cholticha Ruangyuttikarn; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; Mulinda Nyirenda; Beatriz Grinsztejn; Jose Henrique Pilotto; Natthapol Kosashunhanan; Marineide Gonçalves de Melo; Joseph Makhema; Victor Akelo; Ravindre Panchia; Sharlaa Badal-Faesen; Ying Q Chen; Myron S Cohen; Susan H Eshleman; Chloe L Thio; Alexandra Valsamakis Journal: J Acquir Immune Defic Syndr Date: 2017-12-01 Impact factor: 3.731
Authors: Wade Ivy; Steve R Nesheim; Sindy M Paul; Abdel R Ibrahim; Miranda Chan; Xiaoling Niu; Margaret A Lampe Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731
Authors: Vincent Soriano; Pablo Labarga; Carmen de Mendoza; José M Peña; José V Fernández-Montero; Laura Benítez; Isabella Esposito; Pablo Barreiro Journal: Curr HIV/AIDS Rep Date: 2015-09 Impact factor: 5.071
Authors: Jennifer C Price; Eric C Seaberg; John P Phair; Mallory D Witt; Susan L Koletar; Chloe L Thio Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Aditya S Khanna; John A Schneider; Nicholson Collier; Jonathan Ozik; Rodal Issema; Angela di Paola; Abigail Skwara; Arthi Ramachandran; Jeannette Webb; Russell Brewer; William Cunningham; Charles Hilliard; Santhoshini Ramani; Kayo Fujimoto; Nina Harawa Journal: AIDS Date: 2019-10-01 Impact factor: 4.177